Právní předpis byl sestaven k datu 04.05.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx nového xxxxx Xxxxxxx I - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx xxx xxx 2024 - Mezinárodní standard Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx republiky xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Českou xxxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 odst. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X xxx xxx 2024 x xxxx xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. JUDr. Xxxxxx, Xx.X., XX.X., x. r.
vrchní xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;
Xxxxxxx č. 1
Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx jazyka
Úvod
Seznam xxxxxxxxxx xxxxx x metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx je každoročně xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx látek x metod xxxx xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.
Xxxx jsou uvedeny xxxxxxx xxxxx xxxxxxxxx x xxxxx Seznamu xxxxxxxxxx látek x xxxxx.
Xxxxxxxx Při xxxxxxx
Xxxxx XXXX xxx daný xxxxx xxxxxxxxxxx jiné xxxxxx, xx období Xxx xxxxxxx v xxxxxx xxxxxxx začínajícím xxxxx před xxxxxxx (xx 23:59 hodin) x den xxxxxxxxxxxxx Xxxxxxx, které xx xx Sportovec xxxxxxxxx, xx xx xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.
Xxxxxxxx stále
To xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx článku 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „xxx xxxxx xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx nebo xxxxxx. Xxx spíše x xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx nebo xxxxxx x jinému xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx jako xxxxxx označeny x xxxxxx jejich častého xxxxxxxxxx xx společnosti xxxx xxxxx sportu. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, diamorfin (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx z následujících xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (xxxx. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx nebo xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.
Tato xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).
S1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on) |
|
|
• |
Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol) |
• |
norboleton |
|
|
• |
androstenedion (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol) |
• |
quinbolon |
|
|
• |
dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on) |
|
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx x podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX ANABOLICKÉ XXXXX
Xxxx xxxx včetně:
Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.
X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky x xxxxxx xxxxxxxxxx, např. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.
X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx EPO (XXXX).
X2.2. XXXXXXXXX XXXXXXX X XXXXXX UVOLŇUJÍCÍ XXXXXXX
X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (XX),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x xxxx agonistické xxxxxxx.
X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. kortikorelin x xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), jeho analogy x xxxxxxxxx, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,
• xxxxxxxxx růstového xxxxxxx, xxxx. AOD-9604 x xXX 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx x tesamorelin,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x tabimorelin],
• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].
X2.3. XXXXXXX FAKTORY X MODULÁTORY XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x jeho xxxxxxx
• xxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxx faktor xxxxxxxx z krevních xxxxxxxx (XXXX)
• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx.
X3 BETA-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx látky.
Všichni xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů xxxx xxxxxxxx.
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;
• xxxxxxxxx vilanterol: maximálně 25 xxxxxxxxxx za 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx než 1000 xx/xx nebo xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx xxxxx a xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx do xxxx xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxxx látky xx xxxxxxx S4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx do xxxx X4.3 x X4.4 jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A |
• |
inhibitory xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, např.: |
- xxxxx snižující xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), xxxx. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. SR9009, XX9011
X4.4.2 xxxxxxxx a xxxxxxxx xxxxxxxx
X4.4.3 meldonium
S4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX A XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI I XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx diuretika x xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. d- x x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Diuretika, xxxx xxxx.:
xxxxxxxxxxxx; amilorid; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; triamteren;
• Vaptany, xxxx. konivaptan, mozavaptan, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, např.:
albumin, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;
• Desmopresin;
• Probenecid;
a xxxxx látky s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x zubní anestezii.
POZNÁMKA
Nález xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx podání inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Terapeutickou výjimku (XX) na tuto xxxxx xxxxx x xx, která již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx v X2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX S XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.
X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx doplňkového xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Zakázané je xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxx a/nebo úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 ml xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X XXXXXXX DOPING
Z xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx a/nebo xxxxxxx xxxx jakýmkoliv xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x technologie xxxxxxx xxxx.
X3.2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx jsou Nespecifické xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX STIMULANCIA
|
• |
adrafinil |
• |
fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx jiné xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx x jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (dimetylamfetamin) |
• |
metylendioxymetamfetamin |
• |
selegilin |
||
|
• |
efedrin3) |
• |
metylefedrin3) |
• |
sibutramin |
||
|
• |
epinefrin (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky
VÝJIMKY
• klonidin;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. d- x l, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Xxxxxxxx látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x konopí (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx
• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx jakoukoliv xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se xxxxxxxxx x xxxxx výrobcem xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx indikací.
P1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx jsou xxxxxxxx pouze v xxxxxxxxxxxxx sportech Při Xxxxxxx a xxx xx xx označeno xxxxxxxx (*) i Xxxx xxxxxx.
• lukostřelba (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky na xxxxxx, akrobatické xxxxx / X-xxxxx a xxxxxxxxx U-rampa / xxx xxx
• automobilový xxxxx (XXX)
• xxxxxxxx xxxxxx (CMAS)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx terč
• xxxxxxxx (xxxxxxx disciplíny) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx také Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) katin (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: je zakázaný xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: zakázaný xxxxx xxx koncentraci x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci v xxxx xxxxx xxx 10 mikrogramů x 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx anestetiky.
5) bupropion, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
Informace
Právní xxxxxxx č. 19/2025 Xx. xxxxx xxxxxxxxx dnem 28.1.2024.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx